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Background: Residual platelet reactivity (RPR) has been shown to be
related to adverse cardiovascular events. However, assessment of residual pla-
telet reactivity was often evaluated in heterogeneous populations including
both patients with stable disease and acute coronary syndrome.
Objectives: We aim to delineate determinants of RPR in a cohort of stable
cardiovascular patients.
Methods: We included 750 stable cardiovascular patients treated for at least
one month with aspirin (n=213), clopidogrel (n=107) or both (n=425). We eva-
luated RPR using collagen platelet aggregation (CPA), collagen being a stimulus
not directly involved in the specific pathways of aspirin and clopidogrel.
Results: Mean age was 65±12 years, 76% were male; the mean duration of
the CV disease was 1.6 years. CPA ranged from 6% to 96% in our population.
CPA was of 41+/-16, 61+/-14 and 28+/-15% in aspirin, clopidogrel and dual
treatment groups, respectively (P<0.001). In univariate analysis of relevant
biological and clinical parameters, antiplatelet drug treatment pattern
(P<0.001), diabetes (P=0.006), hypertension (P=0.01) and a pain-free walking
distance < 200m (P=0.02) were associated with CPA. Multivariate analysis
showed that antiplatelet drug treatment pattern (P<0.0001) and diabetes
(P=0.0007) were independent factors associated with CPA.
Conclusion: Aspirin had a more pronounced effect on CPA than clopido-
grel in stable cardiovascular patients. Even after adjustment for antiplatelet
drug pattern, diabetes remains an independent factor associated with CPA.
These results give new insight into the controversy about the beneficial effect
of antiplatelet drugs in this particular group of patients
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Thyroid hormones, cortisol and insulin affect the metabolism of myocardial
cells. Their secretion can be altered in case of ST elevation acute myocardial
infarction (STEMI) and their prognostic value is not well established.
The aim of this study was evaluate the hormonal profile and its correlation
with patient’s outcome in STEMI.
Methods and results: 186 consecutive patients (162 males, 87%) with
STEMI were prospectively enrolled. Blood sampling for insulin, cortisol, thyreos-
timulin (TSH), free thyroxin (FT4), triiodothyronin (T3) and free triiodothyronin
(FT3) level measurements were performed in the 24 hours after admission.
Patients who died within the first 24 hours were excluded. Mean follow-up period
was 17,2 [12-28.8] months. We distinguished 2 groups, with (MACE1+) and
without (MACE1-) in-hospital complications (Death and/or shock and/or left ven-
tricular insufficiency and/or myocardial infarction and/or revascularization) and 2
groups, with (MACE2+) or without (MACE2-) late complications (Death and/or
cardiac insufficiency and/or myocardial infarction and/or revascularization).The
mean age of patients was 58.4 ± 12.6 years. 77.9% were smokers, 35.4% were dia-
betics, 37% were hypertensive, 18.8% had a dyslipemia, 17.2% had a history of
familial coronary disease and 4.3% of patients had a renal insufficiency. Hormonal
levels were as follows: insulin=12.6±20.5 mU/l, cortisol=250.4±37 ng/ml,
TSH=2.3±8.3μU/l, FT4=10.2±3 ng/l, T3=0.83±0.23 pg/l, FT3=2.04±3ng/l. Diffe-
rences in hormonal levels between MACE1+ and MACE1- groups were signifi-
cant for cortisol (289.5±304.9 vs 217.5±110.2 ng/l, p=0.033) and T3 (0.83±0.23 vs
0.77±0.2 pg/l, p=0.001). Threshold values determined by ROC curves were 380
ng/l for the cortisol and 0.95 pg/l for T3. In a multivariate model, only T3 was
independently correlated with in-hospital outcome (OR=3.9, IC [1.6-9.8]). There
was no correlation between hormonal levels and late outcome.
In Conclusion: T3 affect short but not long term STEMI prognosis. The
usefulness of routine hormonal measurement and the therapeutic implications
are still to determine. 
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Purpose: To describe antiplatelet treatment patterns over 12 months in
patients with acute cornary syndrome (ACS) undergoing percutaneous coro-
nary intervention (PCI).
Methods: The AntiPlatelet Treatment Observational Registry (APTOR) is
a prospective, international observational study that recruited ACS patients
undergoing PCI in 2007-08, capturing practice patterns, treatment and res-
sources use over 12 months. Interventional cardiologists collected data from
ACS event to hospital discharge and general practitioners and cardiologists
collected follow-up data.
Results: 483 eligible ACS-PCI patients had mean age 61 (13) years, mean
weight 80 (15) kg, were 18% female, 47% with ST-elevation MI (STEMI) and
53% with unstable angina or non-ST elevation MI (UA/NSTEMI). Follow-up
data up to 12 months are available for 396 (82%) patients. Among patients
who were discharged and had follow-up data, 94% were receving clopidogrel
at time of hospital discharge. Cardiovascular combination therapy was pres-
cribed as follows: aspirin (95%), statins (82%), beta-blockers (82%), ACE
inhibitors/ARBs (68%); each of these treatments was globally maintained over
12 months. Lifestyle therapies increased over 12 months from 12% to 57% for
formal diet program and 11% to 48% for formal exercise program. Over 12
months, on 394 patients, overall clopidogrel use was 94% at 30 days, 80% at
6 months, and 75% at 12 months. Amongst 83 patients who stopped clopido-
grel before 12 months, 48% discontinued during the first three months.
Conclusions: These prospective data showed that after an ACS event 20%
of patients have already dropped out their clopidogrel treatment at 6 months
and 25% at 12 months.
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Background: Inadequate anticoagulation in patients undergoing percuta-
neous coronary Intervention (PCI) is associated with more frequent periproce-
dural ischemic events.
Methods: We evaluated the ability of the bedside Hemonox test to identify
patients with an anti-Xa activity level out of the therapeutic range in 296 unse-
